Sunday is going to be a great day for Celgene....
From Wells Fargo 2014 ASH Planner:
Sunday, December 7:
• Key presentations include interim ph.III ASPIRE data from AMGN's Kyprolis
in MM (mid-day), updated data from CELG's registrational MM-020/FIRST
study of front-line Revlimid focused on cuts by age, and ph.I remission data for
AGIO/CELG's IDH2 inhibitor AG-221 in hematologic malignancies.
• Other potentially interesting presentations include expanded (ph.IIIb)
data for CELG's pomalidomide in refractory MM, updated ph.II data from
XLRN/CELG's ACE-536, various presentations on JNJ/Genmab's promising anti-
CD38 antibody for MM, daratumumab, as well as a special symposium in the
morning on CAR-T therapy.
• Key posters include updated analyses of PCYC's RESONATE ibrutinib ph.III,
clinical activity for INFI's duvelisib (IPI-145) in CLL and ibrutinib failures, and
ph.II data from XLRN/CELG's sotatercept in MDS.
• Other interesting posters include several reports of eculizumab aHUS experiences, incremental data
from idelalisib combo therapy for NHL and an ibrutinib biomarker analysis for NHL, updated ph.III data
from SNY's recently-launched oral Gaucher drug eliglustat, ph.I(b)/II(a) results for TLOG's birinapant in
relapsed MDS, several early results for SGEN's b-vedotin, early data from new PI3K, CD37, complement,
CDK4/CDK6, and Syk/Jak (PTLA) inhibitors, more NVS CAR-T data, ABBV's ABT-
199+bendamustine/Rituxan in CLL, early clinical results for CELG's next-generation IMiD CC-122, and
initial data for CALA's glutaminase inhibitor CB-839.
• Events: CELG, CTIC investor events takes place in the evening.
Former world class CFO and new President Hematology and Oncology Dr Fouse running the show Sunday - never felt more confident.....added right here 113.50s
Sure with some of the ASH disasters of the past PDF (Pre-Dr Fouse)...there are STILL some who trim into ASH....but this is Dr Fouse's first ASH analyst conference she is running as President of hematology and oncology and I am sure she has prepared for months for it. Also with Peter K's comments this week at DB, we are sure now drugs from partners will be a big part of the discussion Sunday night (AGIO and XLRN at the top of the list)...Also the AGIO halo (CELG owns GLOBAL rights to AG-221 and OUS to AG-120 and 14% of AGIO stock) will get brighter Sunday/Monday.
Added on this dip and will be adding more today.
IN DR FOUSE WE TRUST!!!!
THE BEST IS YET TO COME!!! 1
Actually, it's because I thought CELG stock price more than priced in wonderful presentations at ASH. Instead of being positioned that way now, I may wait until their actual presentations soon.
I love Cramer. I got all my best stock picks from him. He is on everyday and has to come up with ideas about stocks. The key part he stresses is that you actually have to do your own homework. If you start with his picks and do the good homework, it is easy to pick great winners like CELG, WWAV, AA, EOG, BABA, SWKS and so on. Out of every 25 or 30 stocks he recommends there tends to be 1 that I actually find interesting after doing the homework. The Biotechs most likely will take another break here in December as fund chase under performers for some beta into year end. These stocks they are playing are total garbage stocks and wont be held past year end. As they buy junk to try to get some beta into year end, biotech will rest and be ready to run going into 2015.
Cramer busted by activist hedge fund for raiding corporate coffers at "The Street" while common stock shareholders continue to get slammed.
I'm not shocked....I am merely saying he was touting the sector this week...or some players in it including celgene. But it makes no difference. You just want to tussle.